Avid Bioservices (CDMO) Reports Q3 Loss of $0.05/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St set to open lower as oil jump, high yields fuel inflation concerns
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Goldman Sachs sees 18% upside for Palantir on sovereign AI growth
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Citi names 5 top chip picks ahead of Q3 earnings
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2019 and Recent Developments
March 11, 2019 4:05 PM EDT-- Achieved Revenue of $13.8 Million, an Increase of 102%Compared to Prior Year Quarter --
-- Signed Project Expansion Orders with Existing Customers Representing $23.8 Million --
-- Completed Process Validation Campaign for Future Commercial Production with Other Validations Ongoing --
TUSTIN, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (NASDAQ: CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and... More



